1. Opening Hook
While most pharma companies were busy blaming pricing pressure and regulators, Shilpa Medicare casually dropped its highest-ever EBITDA and called it “just momentum.”
Apparently, asset utilization is the new caffeine.
Between peptides, polymers, NCEs, biologics, and transdermal patches, Shilpa now wants to be everything everywhere all at once—minus the Marvel budget. Management sounded confident, numbers looked obedient, and the future was painted in bold FY27 colours.
But before you assume this is another “great quarter, trust us bro” story, keep reading.
Because behind the scientific jargon and clinical trial timelines lies a very deliberate monetisation plan.
And yes—NorUDCA is the new buzzword you’ll hear a lot more going forward.
2. At a Glance
- Revenue ₹372 cr (+7%) – Not explosive, but steady enough to keep analysts awake.
- EBITDA ₹110 cr (+21%) – Triple digits achieved; management visibly proud.
- EBITDA Margin 30% – Pharma flex unlocked, cost discipline finally showed up.
- PAT ₹44 cr – Calm, composed, and already beat last year’s full-year PAT.
- ROCE ~17% (adjusted) – After years of embarrassment, capital finally behaving.
- Net Debt ₹569 cr – Capex-heavy, but CFO swears interest costs are now “stable.”
3. Management’s Key Commentary
“This quarter marks a very big breakthrough for us.”
(Translation: Please ignore the last few years and focus only on this slide 😏)
“We are operating in high entry barrier segments like APIs, biologics, peptides.”
(Translation: Complexity is our moat… and also our excuse)
“Commercial supplies for NCEs to start from Q4 FY26.”
(Translation: Not yet, but please model it anyway)
“Semaglutide remains a very important product for us.”
(Translation: Yes, we’re late—but the market is huge 😐)
“NorUDCA is a very differentiated opportunity.”
(Translation: Finally, an NCE we can actually sell 💊)
“We will monetize our investments over the next 3–5 years.”
(Translation: Capex era ending, harvesting season coming 🌾)
“We don’t expect much generic competition in Europe this quarter.”
(Translation: Enjoy the margins while they last)
4.
